acomplia

Acomplia know as well as rimonabant is an anti-obesity drug. It was approved for marketing in the European Union in June 2006. Acomplia is not yet approved for use in the United States, where it is known as Zimulti. Current medication is the first in a new class of therapeutic agents called Cannabinoid-1 Receptor Blockers (CB1) destined to treat obesity and related conditions. Acomplia is used complementary to diet and exercise to